3 results
To evaluate the long-term safety and tolerability of elsubrutinib and upadacitinib given alone or as the ABBV-599 (elsubrutinib/upadacitinib) combination in SLE subjects who have completed the M19-130 Phase 2 study.
The main objective of this study is to evaluate the safety and efficacy of ABBV-105, upadacitinib, and ABBV-599 versus placebo for the treatment of signs and symptoms of SLE in participants with moderately to severely active SLE and to define doses…
The objective of this study is to obtain further data on the safety and performance of the Stellarex Balloon in the treatment of lesions in *below the knee* popliteal (P3 segment) and infra-popliteal arteries according to the Instructions for Use in…